Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc. could be a weak company given it's low Piotroski F-score. The momentum for this stock is not very good. Reata Pharmaceuticals, Inc. is not a good value stock. Reata Pharmaceuticals, Inc. is a mediocre stock to choose.

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identify...

News

Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock

PR Newswire Kirby McInerney LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of Reata Pharmaceuticals, Inc. Common Stock Kirby McInerney LLP Announces Pendency of Class Action...\n more…

SG Americas Securities LLC Lowers Position in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Zolmax SG Americas Securities LLC trimmed its holdings in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA Free Report) by 44.4% in the 2nd quarter, according to its most recent disclosure with...\n more…

SG Americas Securities LLC Lowers Holdings in Reata Pharmaceuticals, Inc. (NASDAQ:RETA)

Zolmax SG Americas Securities LLC decreased its stake in shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA Free Report) by 44.4% in the second quarter, according to its most recent Form 13F filing...\n more…

Reata Pharmaceuticals (NASDAQ:RETA) Now Covered by StockNews.com

Ticker Report StockNews.com assumed coverage on shares of Reata Pharmaceuticals (NASDAQ:RETA Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the...\n more…

Biogen completes acquisition of Reata Pharmaceuticals

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Biogen Completes Acquisition of Reata Pharmaceuticals

Globe Newswire Reata acquisition bolsters Biogen s rare disease portfolio with the addition of SKYCLARYS (omaveloxolone), the first and only FDA approved treatment for Friedreich s ataxia in the U.S. CAMBRIDGE...\n more…